Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Expands Anti-Infective Portfolio With $1.9 Bil. Vicuron Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Vicuron's near-term candidates include the antibiotic dalbavancin, which has a Sept 21 user fee deadline, and the antifungal anidulafungin, also pending at FDA. Pfizer's acquisition of Vicuron is expected to close in the third quarter.

You may also be interested in...



Durata Sets Sights On Commercialization As Dalbavancin Nears Filing

After completing an initial public offering in July, announcing plans to relocate its corporate headquarters to Chicago in November and releasing positive Phase III data on its lead drug, the antibiotic dalbavancin, Dec. 11, Durata Therapeutics is laying the groundwork to transition to a commercial drug company.

Durata Sets Sights On Commercialization As Dalbavancin Nears Filing

After completing an initial public offering in July, announcing plans to relocate its corporate headquarters to Chicago in November and releasing positive Phase III data on its lead drug, the antibiotic dalbavancin, Dec. 11, Durata Therapeutics is laying the groundwork to transition to a commercial drug company.

Dalbavancin Delay: Pfizer Pulls NDA To Conduct Extra Phase III Trial

Additional study for the antibiotic will take 18 months to complete, company says

Related Content

Topics

UsernamePublicRestriction

Register

PS062396

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel